Return to Home Page

Scientific Background on Taurox™

Articles and Presentations on Taurox™

Taurox™, a small organic molecule with molecular weight of 724, is a chemical combination of the nutrient taurine and a derivative of the amino acid alanine. Taurine is an important nutrient in the development and support of brain and retinal tissue while beta-alanine is a portion of Vitamin B5. The complete chemical name is carbobenzoxy-beta-alanyl taurine or COBAT. In some reports, it is called Taurox SB.

Double-Blind Placebo-Controlled Trials

The initial study of 39 patients was double-blind and placebo-controlled. 92% of those receiving Taurox™ were identified as having physiological effects, while an apparent physiological placebo effect was observed in 26% of patients where placebo was given. These data were determined to be statistically significant.

The essential characteristics, the Materia Medica (ie: the expected claims for Taurox™), are indicated below:

Materia Medica

  • Increasing Energy
  • Headaches
  • Colds
  • Viruses
  • Allergies
  • Muscle Aches and Pains
  • PMS
  • Neurological Problems
  • Appetite Abnormalities
  • Irritable Bowel Syndrome, loose stools
  • Coughs

Animal Studies

In both pet animals and laboratory mice, Taurox™ was shown to be a powerful immune modulator (Knight et al 1994; Miller et al 1998, 1999; Taub et al 1998, 1999, 2000). In low concentrations Taurox™ was found to modulate erythropoiesis by sustaining the proliferative potential of human BFU-E initially deprived of erythropoietin. Taurox™ also modulated immune responses as revealed by stimulation of the lysis of SRBC by muringe splenocytes in cell culture and in vivo studies as a sole agent showed potent antitumor effects against melanoma and myeloma models at low doses with negligible toxicity. (Knight et al 1994)

Toxicity Studies

Several studies suggest that Taurox™ (as other attenuated substances) has an unusually wide margin between the effective dose and the amount of material that can be harmful.

Single-dose studies of Taurox™ in adult male and female CD-1 mice suggested a maximally tolerated dose (MTD) of about 150mg/kg administered as an IV bolus. Acute toxicology studies did not demonstrate an acute lethal response until doses exceeding 133 mg/kg of Taurox™ were reached. Thus, the toxic doses levels of the compounds appear high (assuming man is like a rat or mouse and not correcting for a different surface-area-to-weight ratio, a dose of 9,975 mg (9.9 g) would not be lethal for a 75-kg person. From a study performed by Dovetail Technologies, Inc. no toxic side effects were observed following either an oral or subcutaneous single 400 ug/kg dose of Taurox™. During the 14-day post-administration period, the animals all gained the appropriate amount of weight as compared to their saline-injected controls and there was no morbidity/mortality. Following euthanasia there were no abnormal findings in the gross necropsies.

Data provided by the University of Maryland and Dovetail Technologies Inc.